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Summary Warfarin inhibits metastasis in the animal model and injection of the Warfarin-dependent coagula-
tion factor complex II, IX, X enhances pulmonary metastasis in the same model. We have studied two possible
mechanisms responsible for the observed effect.
Mtln3, rat mammary carcinoma cells, radiolabelled with 5-(125) Iodo-2'-deoxyuridine (IUDR) were injected
intravenously in female Fisher 344 rats either alone or in combination with factor complex II, IX, X or bovine
serum albumin. Following sacrifice at various intervals, measured lung radioactivity was significantly higher
(20%) in animals administered cells with the factor complex than in the other two groups (P<0.001, ANOVA
and Student's t-test). These results indicate increased entrapment of tumour cells in the pulmonary micro-
circulation.
In a second experiment, rat factor complex II, IX, X was prepared, and Mtln3 cells were then injected in
female Fisher 344 rats alone or in combination with either human factor complex or rat factor complex.
Following sacrifice, the number of pulmonary nodules in animals receiving cells with rat factor complex was
similar to that in animals receiving human factor complex, and significantly higher than that in the control
(P<0.001, ANOVA and Mann-Whitney), indicating that the observed enhancement of pulmonary seeding is
unrelated to the xenogeneic properties of the human factor complex.
Evidence from both experimental and clinical studies show a
clear relationship between the coagulation system and the
spread and growth of malignant disease (Wood, 1958;
O'Meara, 1968; Hilgard & Thornes, 1976; Sun et al., 1979;
Rickles & Edwards, 1983). Animal experiments have sug-
gested that the coagulation system may play a role in the
blood-borne metastasis of tumour cells (Ryan et al., 1968;
Brown, 1973; Wood, 1974; Poggi et al., 1978). The antimeta-
static effect of Warfarin therapy has been demonstrated in
several animal experimental models (Ryan et al., 1969; Hil-
gard et al., 1977; Williamson et al., 1980).
We have demonstrated the inhibitory effect of Warfarin on
pulmonary metastasis in an animal experimental model (Mc-
Culloch & George, 1987). We have also shown, however,
that administration of the Warfarin-dependant factor com-
plex II, IX and X enhances pulmonary seeding in a similar
model. This effect was not observed on administration of
factor VII alone or bovine serum albumin (McCulloch &
George, 1988). The exact mechanism by which factor com-
plex II, IX and X enhances pulmonary tumour cell seeding
remains unclear. We are currently investigating a number of
possible mechanisms which could explain this observed effect.
Amongst the possible explanations considered, were an inc-
rease in tumour cell entrapment in the pulmonary capillary
bed and an effect on the host immune system caused by
injection of xenogeneic (human) proteins.
The present studies were designed to determine the effect
of the factor complex on pulmonary entrapment of tumour
cells and whether the xenogeneic property of the human
factor complex was responsible for the enhancement of pul-
monary seeding previously demonstrated.
Materials and methods
Animals
Female Fisher 344 rats (Olac Limited, Bicester, UK), 6-8
weeks old, mean weight 140 g, were used in all experiments.
Animals were fed a standard laboratory diet (CRM diet,
Labsure, Cambridge, UK) and tap water with a chlorine
content of 7 mgl. All animals were healthy according to
visual observations, and to the results of routine micro-
biological testing for infection.
Tumour cells
A clone of rat mammary carcinoma cells designated Mtln3,
originally derived by Neri and Nicolson (Neri et al., 1982)
from the 7,12-dimethylbenz (a) antracene-induced adenocar-
cinoma 13762 (Segaloff, 1966), were cultured in 75 cm2 tissue
culture flasks (Gibco, Paisley, UK) in equal parts of Hams'
FI0 and Dulbecco's modified Eagles' Medium (F10/DMEM),
with 10% foetal calf serum (FCS) but without antibiotics.
Cultures were maintained at 37°C in equilibrium with 2%
CO2 in air. Cells were passaged a maximum of six times
between thawing and use to minimise problems of pheno-
typic drift (Neri & Nicholson, 1981).
Experimental model ofmetastasis
Mtln3 tumour cells were prepared from subconfluent cultures
as described above, washed, resuspended in F10/DMEM
alone, and density and viability assessed using a Coulter
model cell counter and Trypan Blue exclusion. All cultures
used were >90% viable. Animals were given tail vein injec-
tions of tumour cells under chloral hydrate anaesthesia. They
were maintained on normal diet and water for 17 days after
injection and then sacrificed by cervical dislocation. Lung
tumour nodules were detected by the method of Wexler
(1966). Briefly, this involves excising the lungs after inflating
them with a 15% solution of india ink via the trachea and
then bleaching the preparation in Fekete's solution for 48 h.
Surface pulmonary tumours show up as white nodules which
can then be counted accurately.
Radio-isotope labelling of tumour cells
The radio-isotope used to label the cells was 5-(125) Iodo-2'-
deoxyuridine (IUDR). To establish the appropriate dose
required to label the cells, a clonogenic assay and microtiter
assay were performed.
Clonogenic assay Twenty flasks each containing subcon-
fluent cultures of Mtln3 cells at the same stage of exponential
growth, were exposed to different concentrations of IUDR
for 24 h, at 37°C, in a dose range of 0.01 .Ci ml-' to
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5.0yCi ml- of medium, with one untreated flask acting as
the control. After appropriate dilution and incubation for 8
days under standard conditions, clones were fixed with
methanol, stained with crystal violet and surviving colonies
counted. Doses of IUDR below 0.07yCi ml-' were found to
have no effect on clonal growth of Mtln3 cells, whereas,
clonogenicity was sharply reduced above this concentration.
Microtiter assay This assay relies on the ability of live cells
to reduce a yellow tetrazolium dye to a purple formazan
product. Full details of the method have previously been
published (Plumb et al., 1989). Doses of IUDR below
0.07 ltCi ml-l were found to have no effect on the growth of
Mtln3 cells, whereas, higher doses inhibited cell growth. As a
result of the above two assays, a dose of 0.05 fLCi ml-' of
IUDR was used to label the tumour cells, for the purpose of
our experiment.
Rat coagulationfactor complexpreparation
Blood was collected from F344 rats into plastic bottles con-
taining 6% sodium citrate in a ratio of 9:1 v/v. After cen-
trifugation, the fresh rat plasma was processed to isolate
factors II, IX and X. A concentrate of rat factor complex II,
IX and X was prepared from the plasma by modifying the
barium citrate precipitation and ammonium sulphate elution
method (Ahmad et al., 1989), used to prepare human coag-
ulation factor complex II, IX and X. The ratios of the factors
II, IX and X varied from 21:10:7 to 11:6:8. For the pur-
poses of this experiment, the batch used had a ratio of
11:6:8. Each rat received a dose of 1 ml of concentrate,
containing 11 units of prothrombin, six units of factor IX
and eight units of factor X.
Human coagulationfactor complexpreparation
A heat treated concentrate of human coagulation factors II,
IX and X, prepared from pooled plasma by cryoprecipitation
and supernatant adsorption with DEAE cellulose, was ob-
tained from Dr R.J. Perry of the Protein Fractionation Cen-
tre, Edinburgh, UK.
Previous experiments have shown that a dose of six units
of prothrombin and factor X, and seven units of factor IX
reconstitutes coagulation in a fully warfarinised rat for ap-
proximately 12 h. This is the dose of Factor Complex that
has been used in all our previous studies wherein we demon-
strated the effect of enhancement of tumour metastases
(McCulloch & George, 1987).
To assess whether this effect is dependent on the time of
administration or on the concentration of the Factors II, IX
and X, the following pilot study was performed:
Seven groups of Female Fisher 344 rats, 6-8 weeks old
were used. All animals were injected intravenously with I04
Mtln3 cells as described above. Additional treatments were
then commenced as follows:
Group A: These control animals received no additional
treatment.
Group B: These animals received one injection of Factor
Complex II, IX, X (6:7:6 Units), at the same
time of tumour cell injection (t = 0).
Group C: These animals received one injection of Factor
Complex II, IX, X (1 of the dose administered in
Group B animals) (t = 0).
Group D: These animals received one injection of Factor
Complex II, IX, X (- of the dose administered in
Group B animals) (t = 0).
Group E: These animals received one injection of Factor
Complex II, IX, X (6:7:6 Units (t=2h).
Group F: These animals received one injection of Factor
Complex II, IX, X (6:7:6 Units (t=4h).
Group G: These animals received one injection of Factor
complex II, IX, X (6:7:6) (t = 6).
Animals were sacrificed at 17 days and pulmonary seeding
assessed by the method of Wexler as previously described.
Pilot study to determine the effect ofFactor complex II, IX, X
on aggregability ofMtln3 tumour cells in vitro
Mtln3 cells were grown in culture as described above, tryp-
sinised, washed and resuspended in F10/DMEM without
FCS at a concentration of IO' cells ml-'. Five such suspen-
sions of cells were stirred very gently and to four of them,
Factor Complex II, IX, X (6:7:6 Units/104 cells) was added,
the fifth cell suspension acting as a control. For 4 h there-
after, the cell suspensions were gently stirred. At several
intervals (0, i, 1, 2 and 4 h), multiple samples of cell suspen-
sions were assessed for viability and aggregability using a
haemocytometer and trypan blue exclusion.
Experiment I - Pulmonary trapping of intravenously injected
tumour cells Mtln3 cells were labelled with IUDR at a dose
of 0.05tiCi ml-' of medium as described above. Representa-
tive inoculum doses were monitored in a gamma counter.
Fisher 344 female rats 6-8 weeks old, were given tail vein
injections of 106 radio-labelled cells. At the same time, addi-
tional treatments were begun as follows:
Group A: These control animals received no additional
treatment.
Group B: These animals received one injection of bovine
serum albumin (Sigma, Poole, UK) in a dose of
30mg in 0.6ml of F1O/DMEM.
Group C: These animals received one injection of Human
Factor Complex II, IX and X as described above.
At the following intervals after injection, three animals per
group were exsanguinated, their lungs removed immediately
and placed in individual containers containing 70% ethanol:
5,10,30min, 1,6,12 and 18h.
The dose of bovine serum albumin used gave the same
protein concentration as the factor complex injection in
Group C. The factor complex preparation and the bovine
serum albumin were passed through a 0.2 micron filter before
injection, for sterilisation and removal of any potentially
embolic material.
Lung radioactivity was measured in a gamma counter and
expressed as a percentage ofthe total amount ofradioactivity
injected. Each sample was counted twice. Comparison of the
three groups was by analysis of variance and the Student's
t-test.
Experiment 2 - Comparison ofeffect ofhuman and ratfactor
complexes on pulmonary tumour seeding Three groups of
eight Fisher 344 female rats, 6-8 weeks old were used. All
animals were injected intravenously with 104 Mtln3 cells as
described above. At the same time additional treatments were
begun as follows:
Group A: These control animals received no additional
treatment.
Group B: These animals received one injection of rat factor
complex II, IX and X.
Group C: These animals received one injection of the
human factor complex II, IX and X.
Animals were sacrificed at 17 days and pulmonary seedings
assessed by the method of Wexler, as described above. Com-
parison of the different groups was made by the Kruskal-
Wallis Test in conjunction with the Mann-Whitney U Test.
Both experiments were repeated twice.
Results
Pilot studies
Human coagulation factor complex: dosage and timing study
The dose of Factor Complex II, IX, X used in our previous
work was validated, since a 50% reduction in the dose or a
2 h delay in the time of administration of the Factor Com-
plex, resulted in abolition of the effect of enhancement of
pulmonary seeding (Figure 1) (P = 0.03, Mann-Whitney).ENHANCEMENT OF TUMOUR SEEDING BY COAGULATION FACTORS II, IX, X 515
I
.
S
S I
A B C D
Group
Table I Effect of factor complex on cell aggregability
Time ofsampling (h)
Groups 0 1 1 2 4
A 2+a 2+a 3+a 2+b 3+c
B 3+a 2+a 3+b 2+b 2+c
C 2+a I +a 2+a 3+a 4+b
D 3+a 2+a 2+a 3+b 2+c
E 1+a 3+a 4+b 2+b 1+c
A: Control - cells. B-E: Cells + factor complex. a >95% viable; b
>75% viable; c > 50% viable; d <50% viable.
* S
E F G
Figure 1 Factor complex/tumour cells-time and dose response.
A: Tumour Cells (T.C.) t = Oh; B: T.C. + Factor Complex (F.C.)
(6:7:6) t=Oh; C: T.C. +F.C. (1 Dose) t=Oh; D: T.C. + F.C.
(* Dose) t =0 h; E: T.C. + F.C. (6:7:6) t 2 h; F: T.C. + F.C.
(6:7:6) t = 4 h; G: T.C. + F.C. (6:7:6) t = 6 h.
Effect of Factor Complex II, IX, X on aggregability of Mtln3
cells in vitro Aggregates of cells were monitored and are
indicated in Table I depending on whether the majority of
cells seen occurred singly (1) or were seen in aggregates of
two (2), three (3) or four (4). Aggregability of Mtln3 cells
remained unaltered when Factor Complex II, IX, X was
added to cell suspensions. Viability of cells gradually de-
creased over a period of 4 h similar to that seen in the
control group.
Experiment I
In all groups, an initial peak and trough of activity was
noted in the first 30min, which was followed by an exponen-
tial decline with time (Figure 2). At 1 h, the activity in the
factor treated rats (Group C) was 82.84%. This was
significantly higher than that in the control (Group A,
62.34%) and that in the rats treated with bovine serum
albumin (Group B, 50.10%); (P<0.001 on analysis of
variance and Student's t-test, Table II). This significant
difference persisted at all times thereafter. At 1 h, but not
thereafter, the difference between groups A and B reached
statistical significance (P = 0.018).
Experiment 2
The number of pulmonary nodules in animals treated with
rat factor complex (Group B) and with human factor com-
plex (Group C) was significantly higher than that in the
control Group A. The median number of tumour seedings
was 25 in Group A, 233 in Group B and 226 in Group C
(analysis of variance and Mann-Whitney U Test, P<0.001).
There was no significant difference between the experimental
groups B and C (P = 0.71), (Figure 3). Rat factor complex
and human factor complex when administered with tumour
cells enhanced pulmonary seeding to a similar degree.
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Discussion
The aim of this study was to identify the process by which
factor complex II, IX and X enhances pulmonary seeding. In
so doing we hoped to achieve a better understanding of the
relationship between the metastatic process and the coagula-
tion system. Such an understanding may have implications in
the prevention and treatment of metastatic disease.
From our earlier experiments, we know that Warfarin
inhibits and injection of factor complex II, IX and X en-
hances, metastasis in an animal model. Also, injection of
factor VII alone or bovine serum albumin does not
significantly affect pulmonary seeding and the enhancing
effect of the factor complex does not appear to be related to
the formation of a fibrin clot. It was also observed that the
major role of coagulation in the metastatic process appeared
to occur in the first 12 h after tumour cells entered the blood
stream. (McCulloch & George, 1987, 1988).
In the first experiment, Omin after injection of tumour
cells, there was a sharp rise in measured radioactivity, in all
Table II Lung radioactivity expressed as percentage of total radioactivity injected
Time after injection
Minutes Hours
5 10 30 1 6 12 18
Group A 67.78±4.44 94.3 ± 1.90 66.28 1.04 62.34±3.17 20.65± 1.5 6.38±2.02 2.23±0.36
(cells)
Group B
(cells + bovine 71.2 ± 3.49 94.1 ±2.67 65.17 1.46 50.10 1.49 32.81 ±8.35 9.76±2.97 3.29±0.57
serum albumin)
Group C
(cells + factor 66.44±6.61 83.8 ±3.78 48.67±3.24 82.84±2.16 49.99±1.99 42.59±2.91 7.95±0.94
complex
II, IX, X)
Mean ± s.e.
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Figure 3 Effect of rat factor and human factor complex on
pulmonary tumour seeding Group A: cells; Group B: cells + Rat
Factor Complex; Group C: cells + Human Factor Complex.
experimental groups. This could be attributed to recirculation
of cells which escaped entrapment on first passage through
the pulmonary capillary bed (Fidler, 1970). At the end of 1 h,
the radioactivity measured in the lungs, of animals admin-
istered factor complex II, IX and X together with tumour
cells, was significantly higher than that in the animals receiv-
ing cells alone or cells with bovine serum albumin, a
difference that persisted till the end of the experiment at 18 h.
This difference can be attributed to increased trapping of
tumour cells in the pulmonary microcirculation and may be a
contributory factor in producing the effect ofenhancement of
tumour seeding in our animal model. The exact reason for
increased tumour cell entrapment remains unclear. We are
currently investigating the possibility that this may be a
result of activation of the coagulation system, either partial
or complete. Interaction between coagulation factors and
platelets may have a role to play here. Platelet aggregation is
triggered by thrombin and occurs around entrapped tumour
cells, in model systems, within 3 h of tumour cell injection
(Sindelar et al., 1975; Crissman et al., 1985). Platelets have
also been shown to enhance adhesion between tumour cells
and the endothelial cells (Crissman et al., 1985; Grossi et al.,
1987).
The enhancement of tumour seeding seen in our previous
experiments could not have been secondary to the xenogeneic
property of the human factor complex used since this study
shows clearly that both the human and the rat factor com-
plex II, IX and X enhance tumour seeding to a similar
degree.
The finding that intravenous injection of coagulation
factors enhances metastasis by increasing pulmonary entrap-
ment of tumour cells may, if extended to the human situa-
tion, have some implication for the current controversy on
the effects of perioperative blood transfusion on survival in
cancer patients. Further work is being carried out to deter-
mine whether one of the three factors in the factor complex
II, IX and X is specifically responsible for enhancing tumour
seeding in the lungs.
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